Monitor upcoming quarterly results for execution on iDose TR and Epioxa commercial launches, which are key to sustaining the 2026/2027 revenue guidance. The pipeline milestones (iDose TRIO Phase 3b, Retina XR Phase 2a data) are the next catalysts.
Drugs in focus
GKOS drug pipeline →iDose TREX
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2b/3
- Time to market
- Unknown; Phase 2b/3 trials typically take 2-4 years to complete, so potential approval would likely be 2028-2030 at earliest, assuming positive data.
- Next catalyst
- None dated
What to watchMonitor for interim or topline data readouts from the Phase 2b/3 program, which could serve as a catalyst. The next meaningful update may come at a major ophthalmology conference. Meanwhile, iDose TR commercial adoption trends and quarterly earnings are the primary near-term drivers for GKOS stock.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $224.41entry
- T+1 · 8d ago +6.39%α +4.02% · $238.74
- T+5 · 4d ago +9.50%α +6.90% · $245.72
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Glaukos filed an 8-K to post a November 2026 investor presentation. The presentation reiterates the company's pipeline strategy across interventional glaucoma and keratoconus, highlights the iDose TR and Epioxa launches, and reaffirms revenue guidance of $1,000M for 2026/2027. No new material financial data or guidance changes were disclosed.
Key Facts
- Investor presentation dated November 2026 posted as Exhibit 99.1
- Revenue guidance midpoint of $1,000M for 2026/2027 as of the Q3 2026 earnings call on 10/28/2026
- Q3 2026 gross margin of 88%
- $340M cash and equivalents; no debt as of 9/30/2026
- 30% topline growth in 2025; 20% 10-year revenue CAGR
- 14 disclosed pipeline programs; 12 currently commercialized products
- Epioxa (epi-on CXL for keratoconus) commercially available since March 2026
- iDose TR FDA-approved for re-administration (Jan 2026); Phase 3b study for iDose TRIO enrolled
- Retina XR IVT multi-kinase inhibitor program (GLK-401) Phase 2a first-in-human trial enrollment complete
- iLution blepharitis program in Phase 2 with completed patient enrollment
Financial Impact
No new financial data; revenue guidance midpoint of $1,000M for 2026/2027 reiterated from prior earnings call
Risk Factors
- Commercial adoption of iDose TR and Epioxa may underperform expectations
- Clinical trial delays or negative data for pipeline programs (iDose TRIO, Retina XR, iLution)
- Reimbursement and payer coverage hurdles for new procedural pharmaceuticals
- Competitive pressure from other MIGS and CXL therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-450710 |
| Document: gkos-ex99_1.htm | 0001193125-26-450710 |
| Document: 0001193125-26-450710-index-headers.html | 0001193125-26-450710 |
| Document: 0001193125-26-450710-index.html | 0001193125-26-450710 |
| Document: 0001193125-26-450710.txt | 0001193125-26-450710 |
Track record
16 reports on GKOS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $242.67 Now $244.88 +0.91% settles Nov 23
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $245.72 Now $244.88 −0.34% settles Nov 20
- Nov 6, 202610d ago 8-K Neutral 3/10 Viewing Entry $224.41 to $245.72 Now $244.88 +9.12% ▲ +9.50% +6.90% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $224.41 to $245.72 Now $244.88 +9.12% ▲ +9.50% +6.90% vs SPY
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $246.70 to $247.16 Now $244.88 −0.74% ▲ +0.19% +1.10% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $246.70 to $247.16 Now $244.88 −0.74% ▲ +0.19% +1.10% vs SPY
- Oct 30, 202617d ago 144 Neutral 3/10 Entry $237.60 to $224.41 Now $244.88 +3.06% ▼ −5.55% −2.85% vs SPY
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $242.48 to $219.98 Now $244.88 +0.99% ▼ −9.28% −4.55% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $184.53 to $184.89 Now $244.88 +32.70% ▲ +0.20% +1.56% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 2/10 Entry $186.63 to $189.55 Now $244.88 +31.21% ▲ +1.56% +2.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers